COVER STORY
NEW AGE Mills, chairman
M. D. ANDERSON
of the department of systems biology at M. D. Anderson Cancer Center, sees drug research mounting a novel attack on the underlying mechanisms of disease.
PERSONALIZED MEDICINE Armed with the decoded human genome, drug researchers and clinicians are working to close the gap between PATIENT AND THERAPY RICK MULLIN, C&EN NORTHEAST NEWS BUREAU
“IF THIS IS GOING to move forward, it is
going to take a whole new approach to science,” says Gordon B. Mills, chairman of the department of systems biology at M. D. Anderson Cancer Center in Houston, part of the University of Texas. While sitting at his desk, on which four computer screens are partially covered by Post-it notes, Mills points to a whiteboard. Nestled between charts and memos hung on the wall, the board holds a long list of the center’s research partners, both academic and industrial. “It is going to require team science,” he says. “And the rate-limiting factor,” he adds amid the swirl of digital and hardcopy scrawl, “is bioinformatics.” Mills is talking about personalized medicine, the practice of catering therapies to the specific genetic profiles of patients and their diseased cells. Fueled by the genetic data and diagnostic tools that emerged in the wake of the decoding of the human genome 10 years ago, personalized medicine
is viewed by many in the health care community as a major shift away from the standard approach of developing drugs that work for the largest number of patients in a given therapeutic category. Work is moving slowly, Mills admits. Although cracking the genetic code enabled drug researchers to make credible claims about the potential to treat diseases such as cancer and central nervous system disorders, significant breakthroughs have been few in the decade-long slog through new genetic data. Pharmaceutical companies, biotechnology firms, and institutional researchers are rallying around personalized medicine, but the timeline to new therapies is still being recalibrated. There is no question that new information on the genetics of human disease is being put to breakthrough use in the development of therapies that target patients most likely to benefit. This, in turn, is leading to a big change in the design of clinical trials.
WWW.C E N- ONLI NE .ORG
17
FE BRUARY 1 1 , 20 0 8
And pioneer targeted therapies—such as Genentech’s Herceptin for breast cancer and Novartis Pharmaceuticals’ Gleevec for lung cancer—constitute a variety of new-age blockbuster drugs from which researchers are still learning. Personalized medicine, however, represents only a thin slice of what is taking place across the health care sector, where blockbuster drugs are still defined as $1 billion-ayear sellers that target the largest number of patients with a disease. And the practice poses a challenge to traditional pharmaceutical companies by suggesting that new drugs will target smaller populations. Change comes slowly in a regulated industry dependent on a complicated health insurance scheme. The Food & Drug Administration and insurance providers are seeking new methods for assessing targeted diagnostic tools and the effectiveness of new therapies. Meanwhile, chemists and biologists are turning to translational re-
COVER STORY
tumors via their anatomical and visual characteristics. The practice, however, has gained a fundamentally new dimension with the decoding of the genome. “What’s changed is that we now have the ability to go beyond anatomic and structural differences,” he says. “We go for underlying mechanisms.” In breast cancer and leukemia, he notes, cancers and patient biology have been classified in order to deliver targeted treatment. The use of hormonal manipulation
to treat breast cancer has been highly effective for more than 20 years for patients with the estrogen receptor, Mills says. More recently, work on the HER2 receptor led to the introduction of Herceptin. Gleevec, effective in the treatment of chronic myeloid leukemia, a cancer characterized by a chromosomal abnormality known as the Philadelphia chromosome, has since been used to treat other diseases with particular molecular mutations. That somewhat serendipitous finding signifi-
IN THE FR E E Z E R
NCI Leads Push To Standardize Management Of Biological Specimens Personalized medicine starts with biological specimens. They are the raw materials, and the raw materials are a mess. The collection, storage, and use of biological material in clinical research reflect the nature of that research. Nearly all of the activity is done for a specific project at one clinic according to protocols established by researchers working only on that project. The quality of materials in most biobanks— long-term storage facilities for biological materials—is inconsistent. “The biomarkers essential to personalized medicine will come about through the study of tumor tissues and DNA in biobanks,” notes Greg Simon, president of the advocacy group Faster Cures. “But the biobanking world is very fragmented.” Researchers routinely invent their own methodologies for collection, storage, and freezing of materials, as well as for making specimens available to other researchers in the kind of collaborative efforts needed to advance personalized medicine. “We have nothing near the standards we need for a national system of biobanks,” Simon says.
of translational research.” Roy S. Herbst, chief of And biobanks need to thoracic medical oncology catch up with research, at the University of Texas M. Compton maintains. “BioD. Anderson Cancer Center, banking to date has only agrees. “We need to stanbeen as labor intensive as dardize the way we collect needed to produce the qualtissue, and we need to eduity of specimen for a given cate first responders—the clinicians who take the biopsies,” says Herbst, who Compton is codirecting a personalized medicine research effort on lung cancer called Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination, or BATTLE. Led by the National Cancer Institute, the health care industry is starting to discuss standardization. “Without high-quality biobanking, there will be no personalized medicine,” says Carolyn Compton, head of the office of biorepositories and biospecimen research at purpose,” she says. But as NCI. ”Personalized medicine technologies have become means designing therapies more sensitive, they have and diagnostics based on the raised the quality bar for the particular molecular makeup specimens being analyzed. of a disease. The molecules NCI has published a set of are in the cells, and the cells best practices, starting with are in the biological specibasic policy documentation. mens. Getting high-quality “The standard will not be data from biobanks is the one-size-fits-all,” she says. basis for the personalized ap“But the first step to estabproach and the sine qua non
WWW.C E N- ONLI NE .ORG
18
FE BRUARY 1 1 , 20 0 8
lishing harmonization across the country is to get people to state what their current policy is—to write it down and make it transparent.” Collaborative research, however, will not wait. NCI has launched a $100 million program in partnership with the National Human Genome Research Institute to dig into the genetic material on three cancers—brain, lung, and ovarian. Called the Cancer Genome Atlas, the project is bringing together a league of academic researchers from across the U.S., armed with the latest highthroughput screening technology, to look at the genome of these cancers, broadly and deeply. Researchers will pool and integrate data from all platforms and make them publicly available. “Much like the Human Genome Project, we are trying to give researchers a new lexicon,” Compton says. The research world is bracing itself. Gordon B. Mills, chairman of the department of molecular therapeutics at M. D. Anderson, says Atlas is the next big thing. “It’s cutting-edge stuff.” He adds that while the research community is anxiously awaiting the results of the project, it is also bracing for a “tsunami” of data. NATIONAL CANCER INSTITUTE
search—a closer linking of laboratory drug discovery and clinical development—and are hunting for biomarkers, molecular indicators of drug efficiency. In the health care community, personalized medicine is seen variously as a fundamentally new medical practice or as a continuation of a nearly century-old tradition, but with better tools and more data. In Mills’s view, cancer therapies have been personalized for a while now, through the long-standing practice of classifying
tion in medicine. “Targeted practices have been going on for a long time,” Sninsky says, “we just haven’t been using the molecular information that has emerged in recent years with the sequencing of the human genome and transcription analyses.” What is new, Sninsky points out, is the shift in the approach to complex conditions such as cardiovascular disease,
cantly increased the market for the drug. Work on these drugs has set the template for research currently getting under way. “We have taken a quantum leap forward over the last five years,” Mills says. “We now have the beginning of a real understanding of what is coming out of the human genome project, and we are developing drugs and tools and approaches to test our hypotheses.”
Alzheimer’s disease, rheumatoid arthritis, and cancer. “These are catch-all diseases that look the same,” he says, “but when you scratch below the surface, you begin to understand that the underlying physiology of similar phenotypes can be fundamentally different.” Researchers are now able to go beyond visual characterization to segregate diseases within traditional categories.
THE LEAP IS occurring, he notes, at a time
The Must-Have Catalog for Your Reference Shelf ONE SOURCE. Over 2,000 USP/NF/FCC grade chemicals and DEA controlled substances – the industry’s most comprehensive collection.
QUALITY IN. QUALITY OUT. Our Integrated QualitySM program is based on industry-standard best practices: cGMP, ISO and governmental regulations plus enhanced testing, documentation and change control. The result: a quality product with documentation to simplify your compliance efforts.
WWW.C E N- ONLI NE .ORG
Discover the new Gold Standard of Chemical Catalogs. Order your FREE catalog today.
19
FE BRUARY 1 1 , 20 0 8
R EQUEST MOR E AT ADI NFONOW.ORG
when fewer than 10% of drugs in clinical trials make it to market. “With all our new knowledge, we are actually doing worse than we were 15 years ago,” he laments, noting that 50% of failures now occur in Phase III trials, maximizing the cost of failure. Mills says genetic research may also provide the solution to this problem by prompting the redesign of clinical trials. “The key right now is the concurrent development of biomarkers and drugs,” he says. “We need, right from the beginning, to put as much effort as we can into identifying a target, making a drug, and identifying which patient you put it in.” M. D. Anderson is testing this approach in a year-old lung cancer clinical trial pilot program called Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination, or BATTLE. The trials, involving patients for whom the traditional lung cancer therapies have failed, entails rounds of biopsies directed at progressively moving each patient toward a targeted treatment. The purpose of the program is to establish a biomarker-based clinical trial protocol for lung cancer while studying the molecular mechanisms of response and resistance to targeted agents. “We are at a kind of crossroads where we have developed a large number of new agents with pharmacologically sound activities,” says Roy S. Herbst, chief of thoracic medical oncology at M. D. Anderson and codirector of the BATTLE trial. “But clearly, to hit the home run, you have to match the right drug to the right patient. It’s easier said than done.” Development of diagnostic techniques for characterizing disease tissue has also become a key focus at some biopharmaceutical companies. Celera, a pioneer in decoding the genome in the late 1990s, has shifted its focus to developing clinical tools for personalized medicine. John Sninsky, vice president of discovery research at Celera, agrees with Mills that such tools are emerging from a tradi-
COVER STORY
pharma—he had been vice president of clinical research for oncology for Novartis, in addition to working for Amgen and Biogen Idec—to develop biologically targeted diagnostics. He sees a more fundamental change occurring. “There are pessimists who see personalized medicine as nothing but words, or say that it isn’t economically feasible,” Parkinson says. “But people don’t understand they are in the middle of a revolution until it’s over.” He sees an entirely new approach to research emerging from the decoding of the genome. “I think we are changing our thinking about what malignancies are and how they should be Sninsky classified and treated,” he says. According to Parkinson, drug researchers have become increasingly good at developing agents against targets but have made little headway in predicting
how that match of therapeutic with target will translate across the range of human malignancies of that type. “Part of the inefficiency is the lack of a close connection between biology as we understand it, and the clinical classification of tumors” under the current system of categorizing patients. Personalized medicine, Parkinson says, starts with changing that relationship. “As a drug developer, I spent the last 20 years either as a clinician or a clinical investigator or running government drug development programs with fantastic people, with great agents able, in vitro, to interfere effectively with what we expected were good targets based on our understanding of cancer biology,” he says. The net result in most cases, however, was a highly imprecise match between a biologically targeted therapeutic and the patient. C ELERA
“Molecular information is now being added to other information,” he says. The volume of that information is changing everything, according to Sninsky. “People used to study one gene their whole life. Now there are 25,000 genes you can study in parallel,” he says. “You can investigate their impact on the disease process rather than just investigate the gene itself.” Tools are now available to survey gene expression in RNA or proteins, he says. The volume of data that needs to be processed in drug research is pushing toward a multidisciplinary pharmaceutical industry, Sninsky says. Chemists and biologists will need to routinely work with computational biologists and cancer bioinformatics experts to develop therapies based on the biological characteristics of disease and then develop trials based on the biological characteristics of patients. Sninsky says he left Roche, where he headed research for Roche Molecular Systems, in 2001 to apply the new tools of genomics to the development of such targeted therapeutics. Similarly, David R. Parkinson, chief executive officer of Nodality, left big
R EQUEST MOR E AT ADI NFONOW.ORG
CLOSING THE GAP is a matter of achiev-
CORPORATION
WWW.C E N- ONLI NE .ORG
20
FE BRUARY 1 1 , 20 0 8
ing better biological characterization, Parkinson argues. “The concept is that, by doing more biological studies around the interface of a particular therapeutic with a particular patient with some sort of malignancy, we will gain a better understanding,” he says. Nodality has developed a “cell flow” technology that characterizes biochemistry or physiology at the level of the individual cell. Parkinson says it is based on work done at Stanford University by Gary Nolan, associate professor of microbiology and immunology, to study the signaling networks of lymphocytes and malignant cells. The company applies a laser beam to cells with fluorescence-labeled antibodies against specific phosphoproteins important in intercellular signaling pathways. “If the cell has signaling-related antigens, the cell will light up,” Parkinson says. The technology provides phosphoprotein levels in individual cells, which indicate the extent to which signaling pathways in cancer cells are activated. “In some sense it is a systems biology way of looking for pathways,” Parkinson says. “You use the technology to measure the quantity of these phosphoproteins in leukemia cells, for example, just as you take them from the person. What you
also do is expose those leukemia cells to a stimulation panel of cytokines or growth factors that are relevant to that leukemic cell population, or to a breast cancer cell population.” Parkinson says Nodality’s business plan is to develop routine tests that match patients to appropriate therapies. The work touches on many of the precepts of personalized medicine, including that of translational research. It also raises the question of how new tests will be regulated and who will pay for them. And it highlights the need for collaboration among industry and academic researchers to expedite the development of affordable new diagnostic tools. Most major pharmaceutical manufacturers have begun to incorporate tenets of personalized medicine, primarily in the use of biomarkers. Some are restructuring research to accelerate the process. Still, industry watchers are skeptical as to whether the large drug companies, which have long focused on broadly applied therapies expected to achieve blockbuster sales, are really committed to developing targeted therapies.
markers and other aspects of personalized medicine take hold in the lab. “I would say it is new,” he says. “It requires additional thinking about how we discover and develop processes, as opposed to just taking a broad population approach to development and commercialization. It really comes into tight focus as you think of taking a diagnostics-led approach.”
Genetics-based diagnostics, he says, focus researchers on biocomplexity and translational research techniques. “As you understand the molecular basis of the pharmaceutical you’re developing, you start with assumptions about the basic mechanism,” Rosenkrantz says. “The more you understand about the human implications, the more things change. This infor-
Bruker Optics
THE BLOCKBUSTER approach does not
ALPHA FT-IR Spectrometer
About the size of a lab notebook, the world‘s smallest FT-IR spectrometer ALPHA will play a big part in your daily routine. Affordable price, plug & play set-up, easy-to-use software, combined with QuickSnapTM accessory modules assure powerful and reliable FT-IR analysis you expect from Bruker.
Meet the new ALPHA at PITTCON 2008 - Booth # 4041 For more information, visit www.brukeroptics.com/ftir
think forward
WWW.C E N- ONLI NE .ORG
21
FE BRUARY 1 1 , 20 0 8
F T-IR
R EQUEST MOR E AT ADI NFONOW.ORG
bode well for big companies grappling with personalized medicine, according to Garth Powis, who chairs the department of experimental therapies at M. D. Anderson. “If you think about it, the blockbuster drug mentality that a lot of drug companies still have is unsustainable,” he says. “If you have a blockbuster drug, you have to treat a lot of patients. If you’re treating only 10% of lung cancer patients, you don’t have a blockbuster.” As can be expected, the big drug companies object to this characterization, although they are used to hearing it from academic researchers, says Wayne Rosenkrantz, external affairs director for evidence-based medicine at AstraZeneca. “But I know what is in our pipeline, and I have a good idea of GlaxoSmithKline’s and Genentech’s pipelines,” he says. Rosenkrantz predicts big pharma will deliver its first genetically targeted therapeutic in three to five years, “with more coming at an accelerated pace after that.” He notes that AstraZeneca has been expanding the use of biomarkers in drug discovery. “A number of years ago, we began requiring a biomarker strategy for development,” he says. “But we’ve learned that strategic thinking needs to start earlier.” Rosenkrantz sees real change as bio-
COVER STORY
!NOVELSCREENING LIBRARYWITH!$-% 4OX CONSIDERATIONS ,%!$,)+% 0!2!-%4%23 s-7!VERAGE s("!CCEPTORS s("$ONORS
$)6%23)49 s/VERDRUGLIKESCAFFOLDS
./6%,49 s)NTERNAL2$OFSCAFFOLD DESIGN
02/0%24)%3 s COMPOUNDS s0URITY VIA ,#-3%,3$ s!LLCOMPOUNDSOBEY n,IPINSKIS2ULEOF nPUBLISHEDSOLUBILITY PARAMETERS nLEADLIKESTRUCTURAL PROPERTY MEDCHEM FILTERS
%!3%/&&/,,/7 50
R EQUEST MOR E AT ADI NFONOW.ORG
s2APIDHITRESUPPLY s%XCLUSIVESUB LIBRARIES
#(%-"2)$'%#/20/24)/. 3AN$IEGO #ALIFORNIA \SALES CHEMBRIDGECOM
777#(%-"2)$'%#/-
CA N C ER I N I TI ATI V ES
Major Research Centers Launch Efforts In Personalized Medicine As drug discovery scientists shift their focus to the molecular characterization of disease, two major cancer research institutes are gearing up with new facilities dedicated to such personalized medicine. Both the Center for Molecular Oncologic Pathology (CMOP), a joint venture of Dana-Farber Cancer Institute and Brigham & Women’s Hospital, and the Center for Targeted Therapy (CTT) at the University of Texas M. D. Anderson Cancer Center will channel their resources and longstanding traditions into a focused investigation of the biology of cancer. The purpose of CTT, according to its director, Garth Powis, who chairs the department of experimental therapies at M. D. Anderson, is to corral all stages of the drug discovery and development process in the design of targeted therapies. M. D. Anderson broke ground on the $95 million center last year. Powis says successful biological characterization of disease will require a more collaborative approach to medicine. It will also require new tools, especially imaging systems, to advance the development of diagnostic biomarkers. “Only with the advent of molecularly targeted agents do you have any degree of confidence that you are inhibiting at least one major dis-
WWW.C E N- ONLI NE .ORG
22
ease target and maybe some minor targets,” Powis says. “The idea is that we all need to work together, because if you are going to do personalized medicine, you have to have biomarkers and the ability to know what tumor the patient has. And probably the best way to do that is to integrate imaging into drug development. The goal is Powis
to achieve personalized medicine.” CMOP is taking a similar approach, according to Massimo F. Loda, director of the center. Its goal, he says, is to apply novel biomolecular diagnostic techniques to human tissue in the development of targeted therapies. The venture brings the partners into a fundamentally new era in cancer research, Loda says. “Personalized medicine is new for the simple reason that for decades we have classified tumors according to what they look like. And we are good at it,” he says.
FE BRUARY 1 1 , 20 0 8
“Now we can identify the genetics of the composition of the tumor. We can precisely target mutations with the kind of certainty that if we were able to identify all mutations in all tumors in real time—which we will in a few years—we would be able to devise individual therapies.” Another goal of the center, Loda says, is to M. D. ANDERSON
./6!#/2% ,)"2!29
develop tests for clinical trials that will be adopted as standards of care. According to Powis, partnerships between research organizations will be important to developing diagnostic techniques and evolving standards for clinical trials in what he characterizes as the very early days for personalized medicine. “Personalized medicine has had very little impact as yet on clinical trials and health care in general,” Powis acknowledges. “Most oncologists are not doing this kind of research, and most patients are not treated in institutions like M. D. Anderson.”
Gain Free Access to Leading-Edge Chemistry Research... Subscribe to the Aldrichimica Acta!
In 2007, the #1 ranked* Aldrichimica Acta celebrated 40 years of providing the chemistry community with open access to high-quality scientific information. The Acta continues to publish review articles on innovative chemistry research written by leading experts from around the world.
Visit sigma-aldrich.com/acta and request your FREE subscription to the Aldrichimica Acta — the first 800 respondents will receive a FREE binder to conveniently store Acta issues!
Upcoming Authors and Topics Prof. Steven V. Ley (U. of Cambridge) Drs. D. Amoroso and K. Abdur-Rashid (KCT) Prof. Benjamin List (MPI) Prof. Jik Chin (U. of Toronto) Prof. M. Christina White (UIUC) Prof. Bruce H. Lipshutz (UCSB)
Practical Organocatalysis with (S)- and (R)-5-Pyrrolidin-2-yl-1H-tetrazoles Aminophosphine Catalysts in Modern Asymmetric Synthesis TRIP—A Powerful Brønsted Acid Catalyst for Asymmetric Synthesis Designer Chiral Diamines by the Diaza-Cope Rearrangement Skip the Oxygen: Allylic Esterifications and Aminations Directly from C-H Bonds Transition-Metal Catalysis in Water at Ambient Temperatures Free Acta binder offer good while supplies last. Allow 6–8 weeks for delivery.
*Impact factor data published by Thomson Scientific’s Journal Citation Reports®.
03961-503520 0027
sigma-aldrich.com
REQUEST MORE AT ADINFONOW.ORG
COVER STORY
“There are pessimists who see personalized medicine as nothing but words. But people don’t understand they are in the middle of a revolution until it’s over.” mation needs to be fed back to the development of diagnostics. We hadn’t done that. We’re learning.” Roche built similar thinking into its year-old decentralized research program, which established five separate research and business organizations for distinct therapeutic areas such as cancer or inflammatory disease. Along with leaders for discovery, development, and business planning, each research group has a leader for clinical research and exploratory development, or CRED. “The point of CRED is to place greater emphasis up front on identifying biomarker strategies and to direct more effort toward understanding disease and disease pathways,” explains Andreas Wallnoefer, corporate head of the CRED initiative at Roche. “We are trying to apply personal-
ized health care throughout the portfolio as a fundamental principle.” BIOMARKERS ARE not a new concept at
Roche, Wallnoefer emphasizes, but they have not been implemented evenly across the entire research enterprise. “We have always used pharmacodynamics and surrogate markers in drug development,” he says. “But with our focus on bridging clinical input to discovery, and our active effort to understand the systems of diseases through systems biology, we felt we needed a more systematic approach.” The company has determined that every drug discovery program needs to have a biomarker strategy. “This will not only help with personalized health care,” Wallnoefer says, “it will improve early development decision-making. It is a strategy that will
help us in terms of improving our R&D productivity—deciding which programs to progress.” At the same time, he says, Roche wants to deliver drugs with better efficacy and lower risks of side effects. Among the furthest advanced personalized medicine programs at Roche is a partnership with Plexxikon to study an investigational cancer therapy that selectively inhibits a mutated form of the BRAF kinase gene, which is involved in numerous cancer pathways. James (Andy) Williams, head of molecular medicine for anti-angiogenesis programs at Pfizer, sees such developments not so much as a revolution but as part of an evolution. “Is personalized medicine new? I don’t think it is,” he says. Pfizer, like most drug companies, has a tradition of adopting new technologies to
Patent, Trademark and Copyright Causes Throughout the World
Metropolitan
R EQUEST MOR E AT ADI NFONOW.ORG
248.641.1600
St. Louis, MO 314.726.7500
Washington, DC 703.668.8000
www.hdp.com
Harnessing Innovation WWW.C E N- ONLI NE .ORG
24
FE BRUARY 1 1 , 20 0 8
R EQUEST MOR E AT ADI NFONOW.ORG
Detroit, MI
MANAGERS AT the big drug companies say the quest to better understanding disease at the molecular level is intriguing work that presents a range of scientific hurdles. But they also point to regulatory hurdles and the question of how the health care benefits infrastructure will evolve to implement and pay for personalized medicine. “Frankly, FDA doesn’t know how to regulate this,” Rosenkrantz says. “We really are working blind on what FDA and payers will require in the way of evidence that new diagnostics and therapies have medical value. We have some questions about whether we should be pursuing this course given all the ambiguity, but ultimately, the answer is that we have to do it, or else there will be no new drugs.” According to Steven I. Gutman, director of the office of in vitro diagnostic device evaluation and safety at FDA’s Center for Devices & Radiological Health, the onus of developing a framework for personalized medicine falls to a large extent on researchers whose first job is to establish that tests are analytically sound and have clinical value. “Establishing analytical performance for these tests is sometimes challenging, but if you haven’t locked in analytical performance you’re playing in a sandbox with no sand,” he says. “It’s a very heterogeneous research community in which there are those who have the analytics nailed down and those who don’t.” Gutman argues that oversight of new practices might evolve within the current regulatory infrastructure. “I’m not sure it is a well thought out proposition that new science calls for a new paradigm at FDA,” he says. “The new technology is daunting
in terms of clinically credentialed technology. But people who think there is a radical paradigm shift have not looked carefully at what we do.” FDA’s general inquiry into the function and efficacy of new diagnostics is straightforward, he says. “We ask questions like, ‘Is the test accurate and repeatable? What is the associated drug impact?’ ” Gutman
explains. “The sponsors should be embarrassed not to be able to answer them.” Gutman notes that personalized medicine is also being monitored closely at the National Institutes of Health. A recent report by the Secretary’s Advisory Committee on Genetics, Health & Society at NIH suggests there are gaps in oversight of genetic testing and calls for public/private
Polymorphism, Salts & Crystallization An Integrated Approach to Solid-State Development
à à à à Ã
Polymorph, Salt and Co-Crystal Screening Selection of the Optimal Form Crystallization Optimization Polymorphic Purity and Amorphous Content Consulting and Patent Support
Solvias provides comprehensive physical chemistry services for the identification and selection of polymorphs, salts and co-crystals, including method development for polymorphic purity and optimization of crystallization processes. With years of drug development experience as former research group of a major pharmaceutical company, we can help you to crystallize your ideas.
1-866-4SOLVIAS
WWW.C E N- ONLI NE .ORG
25
[email protected] FE BRUARY 1 1 , 20 0 8
www.solvias.com
R EQUEST MOR E AT ADI NFONOW.ORG
conduct exploratory research, Williams maintains. He notes, for example, that cholesterol is a long-standing biomarker for cardiovascular disease and that the predictive value of biomarkers for cancer have been studied for years. “We have invested in personalized medicine for a long time,” he says, “though we had different terminology for it.” Pfizer is integrating personalized medicine into drug research in part through partnerships. For example, the firm recently announced it is collaborating with Source MDx on the development and validation of RNA-based pharmacodynamic and predictive biomarkers within Pfizer’s cancer and inflammation therapy development programs.
COVER STORY
INSURANCE FOR personalized
R EQUEST MOR E AT ADI NFONOW.ORG
clinical treatment presents another hurdle. Experts point to the irony that, at the dawn of an age of personalized medicine, the doctorpatient relationship is at its least personal. Doctors are paid by the number of patients they see, not for the time they invest in a personalized health maintenance regime or for health outcomes. IBM is among the health care inGrundy Scott surance purchasers trying to change cepts of personalized medicine. The colthe system. “We are really unhappy with laborative is coordinating comprehensive the current structure, in which we can buy health care pilots in at least six locations episodic care based around procedures or around the country. processes, but we can’t purchase a comComing to an agreement on a payment prehensive care structure with meaningful structure poses a problem, according to doctor-patient relationships,” says Paul Kathryn A. Phillips, professor of health Grundy, director of health care, technolcare and economics at the University of ogy, and strategic initiatives at IBM. “We California, San Francisco. “Where is the can buy an amputation for a diabetic, but evidence in personalized medicine? What we can’t buy the kind of doctor-patient do payers want in terms of evidence? How relationship that will prevent that amputado they view and use it? This is the key to tion from needing to be done.”
WWW.C E N- ONLI NE .ORG
26
FE BRUARY 1 1 , 20 0 8
coverage and reimbursement,” she told attendees at a conference hosted by Burrill & Co. in San Francisco last November. “The payers are reluctant to be proactive unless they see the value of these products.” The problem, she says, stems from a lack of clinical data outcomes and economic evaluations, as well as a lack of industry incentives to provide adequate information for coverage decisions. Technical assessment guidelines need to be developed and risk needs to be shared. Her assessment echoes a call by the Secretary’s Advisory Committee on Genetics, Health & Society at NIH for public/private partnerships to close the gaps in regulatory oversight. The public is not waiting. Awareness of personalized medicine is increasing with the rise in news coverage of technologies for early cancer detection and determining genetic propensities for disease. Do-ityourself genetic testing kits are now available, and private companies offer routine screening. For example, Navigenics, a Redwood Shores, Calif.-based genomics testing service, charges $2,500 for an initial genetic scan and counseling session, and $250 per year for its customers, which the firm calls members, for follow-up scans. Navigenics CEO Mari Baker says public interest in taking advantage of genomics technology will ramp up, with the effect of lowering costs and making the technology more accessible. The ability to use genetic G ENOM I C HEA LTH
Grundy also chairs the Patient-Centered Primary Care Collaborative, a 107-member coalition of private and public buyers of health care benefits, public health care agencies, and major insurance companies investigating new health care payment structures that will employ diagnosticbased preventive medicine and other preI BM
partnerships to assess and fill them. Regulatory oversight should advance as the science does, according to Gutman, who quips that for once it may be the science holding things up. “It’s not the damned FDA, it’s the damned science,” he says. “It’s my view that if sponsors have good science and they bother to write it down in a coherent package, it goes flying through FDA faster than a speeding rocket.”
data to attain early treatment for disease will help encourage acceptance of personalized medicine, outweighing concerns about abuse of data by employers or others, Baker says. President George W. Bush, she notes, has said he will sign a bill currently before Congress that prevents the use of genetic testing by employers or insurers.
NEW
TM
[ POWERFUL MODIFICATION ]
[ POWERFUL CROSSLINKING ]
TRY OUR
SELECT BIOTIN
LABELS,
CLICK REAGENTS, HAPTENS AND PEPTIDE
REAGENTS EACH WITH A RANGE OF SPECIFIC SIZE OPTIONS OF OUR dPEGTM SPACERS
DISCOVER FOR YOURSELF HOW WE ARE
LEADING THE WAY THROUGH MONODISPERSE dPEG™ INNOVATION
FAX YOUR ORDERS TO 614 760-9781 OR E-MAIL
[email protected] REQUEST MORE AT AD I N FON OW.ORG
personalized medicine is the promise of cost savings. AstraZeneca’s Rosenkrantz says the potential efficiency gain is a major incentive for insurers to work with the research and medical communities to build personalized and preventive medical treatment into the health care system. Meanwhile, innovators are finding their way into the mainstream. Genomic Health, for example, has developed a diagnostic tool for breast cancer that CEO Randal W. Scott says currently holds 30% of the market for testing node-negative, estrogen receptor-positive patients, who account for half of all breast cancer patients. “It does take a significant effort to get reimbursed,” Scott acknowledges. “But our test meets American Society of Clinical Oncology and National Comprehensive Cancer Network clinical guidelines. All the major payers are onboard, including Medicare and United Healthcare.” Genomic Health’s Oncotype DX uses gene expression technology similar to RTPCR (reverse transcriptase-polymerase chain reaction) scanning, a mainstay in HIV viral load testing, to test tumor biopsies. The company is adapting the technology to scan other cancers, including colon, lung, and prostate. Scott says a colon cancer product may be validated next year and on the market by 2009. From Scott’s perspective, medicine is in the midst of a “revolution driven by tools.” He compares the growth of acceptance of the technology to Moore’s Law (the axiom that the number of transistors on a computer chip would double every two years) in the electronics industry. “The potential power of new technology is accelerating rapidly and will significantly impact drug use,” he says. FDA’s interest is clear enough to Scott that he sees the potential for increased regulation in the clinic and the laboratory. “It is important to get the balance right,” Scott says, adding that effective translational research will be crucial to success. “The key to it all is good clinical medicine.” ■
OUR
R EQUEST MOR E AT ADI NFONOW.ORG
PERHAPS THE BIGGEST selling point for
REVOLUTIONIZING BIOCOMPATIBILITY WITH EXCLUSIVE dPEG REAGENTS
WWW.C E N- ONLI NE .ORG
27
FE BRUARY 1 1 , 20 0 8
